Dosing & Uses
Dosage Forms & Strengths
tablet
- 12.5mg
- 25mg
- 32mg
tablet, chewable
- 25mg
Motion Sickness
12.5-50 mg PO given 1 hour before travel and then every 24 hr PRN
Vertigo
25-100 mg/day PO in single daily dose or divided q6-12hr
Dosage Forms & Strengths
tablet
- 12.5mg
- 25mg
- 32mg
- 50mg
tablet, chewable
- 25mg
Motion Sickness
<12 years: Safety and efficacy not established
>12 years: 12.5-50 mg PO given 1 hour before travel and then daily PRN
Vertigo
<12 years: Safety and efficacy not established
>12 years: 25-100 mg/day PO in single daily dose or divided q6-12hr
Interactions
Interaction Checker
No Results

Contraindicated
Serious - Use Alternative
Significant - Monitor Closely
Minor

Contraindicated (0)
Serious - Use Alternative (5)
- metoclopramide intranasal
meclizine, metoclopramide intranasal. Either increases effects of the other by Other (see comment). Avoid or Use Alternate Drug. Comment: Avoid use of metoclopramide intranasal or interacting drug, depending on importance of drug to patient.
- olopatadine intranasal
meclizine and olopatadine intranasal both increase sedation. Avoid or Use Alternate Drug. Coadministration increases risk of CNS depression, which can lead to additive impairment of psychomotor performance and cause daytime impairment.
- pramlintide
pramlintide, meclizine. Either increases effects of the other by pharmacodynamic synergism. Contraindicated. Synergistic inhibition of GI motility.
- ropeginterferon alfa 2b
ropeginterferon alfa 2b and meclizine both increase Other (see comment). Avoid or Use Alternate Drug. Narcotics, hypnotics or sedatives can produce additive neuropsychiatric side effects. Avoid use and monitor patients receiving the combination for effects of excessive CNS toxicity.
- secretin
meclizine decreases effects of secretin by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Concomitant use of anticholinergic drugs may cause a hyporesponse to stimulation testing with secretin. Discontinue anticholinergic drugs at least 5 half-lives before administering secretin.
Monitor Closely (115)
- abobotulinumtoxinA
abobotulinumtoxinA increases effects of meclizine by pharmacodynamic synergism. Use Caution/Monitor. Use of anticholinergic drugs after administration of botulinum toxin-containing products may potentiate systemic anticholinergic effects.
- aclidinium
meclizine and aclidinium both decrease cholinergic effects/transmission. Use Caution/Monitor.
- acrivastine
acrivastine and meclizine both increase sedation. Use Caution/Monitor.
- amantadine
meclizine, amantadine. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Potential for increased anticholinergic adverse effects.
- amifampridine
meclizine increases toxicity of amifampridine by Other (see comment). Modify Therapy/Monitor Closely. Comment: Amifampridine can cause seizures. Coadministration with drugs that lower seizure threshold may increase this risk.
- amisulpride
amisulpride and meclizine both increase sedation. Use Caution/Monitor.
- amitriptyline
meclizine and amitriptyline both decrease cholinergic effects/transmission. Use Caution/Monitor.
- amoxapine
meclizine and amoxapine both decrease cholinergic effects/transmission. Use Caution/Monitor.
- anticholinergic/sedative combos
anticholinergic/sedative combos and meclizine both decrease cholinergic effects/transmission. Use Caution/Monitor.
- aripiprazole
meclizine decreases levels of aripiprazole by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
meclizine decreases levels of aripiprazole by pharmacodynamic antagonism. Use Caution/Monitor.
aripiprazole increases effects of meclizine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. - asenapine
asenapine and meclizine both increase sedation. Use Caution/Monitor.
- asenapine transdermal
asenapine transdermal and meclizine both increase sedation. Use Caution/Monitor.
- atracurium
atracurium and meclizine both decrease cholinergic effects/transmission. Use Caution/Monitor.
- atropine
atropine and meclizine both decrease cholinergic effects/transmission. Use Caution/Monitor.
- atropine IV/IM
atropine IV/IM and meclizine both decrease cholinergic effects/transmission. Use Caution/Monitor.
- avapritinib
avapritinib and meclizine both increase sedation. Use Caution/Monitor.
- belladonna alkaloids
belladonna alkaloids and meclizine both decrease cholinergic effects/transmission. Use Caution/Monitor.
- belladonna and opium
meclizine and belladonna and opium both decrease cholinergic effects/transmission. Use Caution/Monitor.
- benperidol
meclizine decreases levels of benperidol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
meclizine decreases levels of benperidol by pharmacodynamic antagonism. Use Caution/Monitor.
benperidol increases effects of meclizine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. - benzhydrocodone/acetaminophen
benzhydrocodone/acetaminophen and meclizine both increase sedation. Use Caution/Monitor.
- benztropine
benztropine and meclizine both decrease cholinergic effects/transmission. Use Caution/Monitor. Additive anticholinergic adverse effects may be seen with concurrent use.
- bethanechol
bethanechol increases and meclizine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- brexanolone
brexanolone, meclizine. Either increases toxicity of the other by sedation. Use Caution/Monitor.
- brexpiprazole
brexpiprazole and meclizine both increase sedation. Use Caution/Monitor.
- brimonidine
brimonidine and meclizine both increase sedation. Use Caution/Monitor.
- brivaracetam
brivaracetam and meclizine both increase sedation. Use Caution/Monitor.
- buprenorphine subdermal implant
buprenorphine subdermal implant and meclizine both increase sedation. Use Caution/Monitor.
- buprenorphine transdermal
buprenorphine transdermal and meclizine both increase sedation. Use Caution/Monitor.
- carbachol
carbachol increases and meclizine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- cevimeline
cevimeline increases and meclizine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- chlorpromazine
meclizine decreases levels of chlorpromazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
meclizine decreases levels of chlorpromazine by pharmacodynamic antagonism. Use Caution/Monitor.
chlorpromazine increases effects of meclizine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. - cisatracurium
cisatracurium and meclizine both decrease cholinergic effects/transmission. Use Caution/Monitor.
- clobazam
meclizine, clobazam. Other (see comment). Use Caution/Monitor. Comment: Concomitant administration can increase the potential for CNS effects (e.g., increased sedation or respiratory depression).
- clomipramine
meclizine and clomipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.
- clozapine
meclizine decreases levels of clozapine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
meclizine decreases levels of clozapine by pharmacodynamic antagonism. Use Caution/Monitor.
clozapine increases effects of meclizine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. - cyclizine
cyclizine and meclizine both decrease cholinergic effects/transmission. Use Caution/Monitor.
- cyclobenzaprine
cyclobenzaprine and meclizine both decrease cholinergic effects/transmission. Use Caution/Monitor.
- daridorexant
meclizine and daridorexant both increase sedation. Modify Therapy/Monitor Closely. Coadministration increases risk of CNS depression, which can lead to additive impairment of psychomotor performance and cause daytime impairment.
- darifenacin
darifenacin and meclizine both decrease cholinergic effects/transmission. Use Caution/Monitor.
- desipramine
meclizine and desipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.
- dicyclomine
dicyclomine and meclizine both decrease cholinergic effects/transmission. Use Caution/Monitor.
- difelikefalin
difelikefalin and meclizine both increase sedation. Use Caution/Monitor.
- diphenhydramine
diphenhydramine and meclizine both decrease cholinergic effects/transmission. Use Caution/Monitor.
- donepezil
donepezil increases and meclizine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- donepezil transdermal
meclizine, donepezil transdermal. Either decreases effects of the other by pharmacodynamic antagonism. Use Caution/Monitor.
- dosulepin
meclizine and dosulepin both decrease cholinergic effects/transmission. Use Caution/Monitor.
- doxepin
meclizine and doxepin both decrease cholinergic effects/transmission. Use Caution/Monitor.
- droperidol
meclizine decreases levels of droperidol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
meclizine decreases levels of droperidol by pharmacodynamic antagonism. Use Caution/Monitor.
droperidol increases effects of meclizine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. - echothiophate iodide
echothiophate iodide increases and meclizine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- esketamine intranasal
esketamine intranasal, meclizine. Either increases toxicity of the other by sedation. Use Caution/Monitor.
- fesoterodine
fesoterodine and meclizine both decrease cholinergic effects/transmission. Use Caution/Monitor.
- flavoxate
flavoxate and meclizine both decrease cholinergic effects/transmission. Use Caution/Monitor.
- fluphenazine
meclizine decreases levels of fluphenazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
meclizine decreases levels of fluphenazine by pharmacodynamic antagonism. Use Caution/Monitor.
fluphenazine increases effects of meclizine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. - galantamine
galantamine increases and meclizine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- ganaxolone
meclizine and ganaxolone both increase sedation. Use Caution/Monitor.
- glycopyrrolate
glycopyrrolate and meclizine both decrease cholinergic effects/transmission. Use Caution/Monitor.
- glycopyrrolate inhaled
glycopyrrolate inhaled and meclizine both decrease cholinergic effects/transmission. Use Caution/Monitor.
- haloperidol
meclizine decreases levels of haloperidol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
meclizine decreases levels of haloperidol by pharmacodynamic antagonism. Use Caution/Monitor.
haloperidol increases effects of meclizine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. - henbane
henbane and meclizine both decrease cholinergic effects/transmission. Use Caution/Monitor.
- homatropine
homatropine and meclizine both decrease cholinergic effects/transmission. Use Caution/Monitor.
- huperzine A
huperzine A increases and meclizine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- hyoscyamine
hyoscyamine and meclizine both decrease cholinergic effects/transmission. Use Caution/Monitor.
- hyoscyamine spray
hyoscyamine spray and meclizine both decrease cholinergic effects/transmission. Use Caution/Monitor.
- iloperidone
meclizine decreases levels of iloperidone by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
meclizine decreases levels of iloperidone by pharmacodynamic antagonism. Use Caution/Monitor.
iloperidone increases effects of meclizine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. - imipramine
meclizine and imipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.
- ipratropium
ipratropium and meclizine both decrease cholinergic effects/transmission. Use Caution/Monitor. Due to the poor systemic absorption of ipratropium, interaction unlikely at regularly recommended dosages.
- lasmiditan
lasmiditan, meclizine. Either increases effects of the other by sedation. Use Caution/Monitor. Coadministration of lasmiditan and other CNS depressant drugs, including alcohol have not been evaluated in clinical studies. Lasmiditan may cause sedation, as well as other cognitive and/or neuropsychiatric adverse reactions.
- lemborexant
lemborexant, meclizine. Either increases effects of the other by sedation. Modify Therapy/Monitor Closely. Dosage adjustment may be necessary if lemborexant is coadministered with other CNS depressants because of potentially additive effects.
- levodopa
meclizine, levodopa. Other (see comment). Use Caution/Monitor. Comment: Anticholinergic agents may enhance the therapeutic effects of levodopa; however, anticholinergic agents can exacerbate tardive dyskinesia. In high dosage, anticholinergics may decrease the effects of levodopa by delaying its GI absorption. .
- lofepramine
meclizine and lofepramine both decrease cholinergic effects/transmission. Use Caution/Monitor.
- loxapine
meclizine decreases levels of loxapine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
meclizine decreases levels of loxapine by pharmacodynamic antagonism. Use Caution/Monitor.
loxapine increases effects of meclizine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. - loxapine inhaled
loxapine inhaled increases effects of meclizine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.
meclizine decreases levels of loxapine inhaled by pharmacodynamic antagonism. Use Caution/Monitor. - lurasidone
lurasidone, meclizine. Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. Comment: Potential for increased CNS depressant effects when used concurrently; monitor for increased adverse effects and toxicity.
- maprotiline
meclizine and maprotiline both decrease cholinergic effects/transmission. Use Caution/Monitor.
- methscopolamine
meclizine and methscopolamine both decrease cholinergic effects/transmission. Use Caution/Monitor.
- neostigmine
neostigmine increases and meclizine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- nortriptyline
meclizine and nortriptyline both decrease cholinergic effects/transmission. Use Caution/Monitor.
- olanzapine
meclizine decreases levels of olanzapine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
meclizine decreases levels of olanzapine by pharmacodynamic antagonism. Use Caution/Monitor.
olanzapine increases effects of meclizine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. - onabotulinumtoxinA
onabotulinumtoxinA and meclizine both decrease cholinergic effects/transmission. Use Caution/Monitor.
- orphenadrine
meclizine and orphenadrine both decrease cholinergic effects/transmission. Use Caution/Monitor.
- oxybutynin
meclizine and oxybutynin both decrease cholinergic effects/transmission. Use Caution/Monitor.
- oxybutynin topical
meclizine and oxybutynin topical both decrease cholinergic effects/transmission. Use Caution/Monitor.
- oxybutynin transdermal
meclizine and oxybutynin transdermal both decrease cholinergic effects/transmission. Use Caution/Monitor.
- paliperidone
meclizine decreases levels of paliperidone by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
meclizine decreases levels of paliperidone by pharmacodynamic antagonism. Use Caution/Monitor.
paliperidone increases effects of meclizine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. - pancuronium
meclizine and pancuronium both decrease cholinergic effects/transmission. Use Caution/Monitor.
- perphenazine
meclizine decreases levels of perphenazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
meclizine decreases levels of perphenazine by pharmacodynamic antagonism. Use Caution/Monitor.
perphenazine increases effects of meclizine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. - physostigmine
physostigmine increases and meclizine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- pilocarpine
pilocarpine increases and meclizine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- pimozide
meclizine decreases levels of pimozide by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
meclizine decreases levels of pimozide by pharmacodynamic antagonism. Use Caution/Monitor.
pimozide increases effects of meclizine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. - pralidoxime
meclizine and pralidoxime both decrease cholinergic effects/transmission. Use Caution/Monitor.
- prochlorperazine
meclizine decreases levels of prochlorperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
meclizine decreases levels of prochlorperazine by pharmacodynamic antagonism. Use Caution/Monitor.
prochlorperazine increases effects of meclizine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. - promethazine
meclizine decreases levels of promethazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
meclizine decreases levels of promethazine by pharmacodynamic antagonism. Use Caution/Monitor.
promethazine increases effects of meclizine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. - propantheline
meclizine and propantheline both decrease cholinergic effects/transmission. Use Caution/Monitor.
- protriptyline
meclizine and protriptyline both decrease cholinergic effects/transmission. Use Caution/Monitor.
- pyridostigmine
pyridostigmine increases and meclizine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- quetiapine
meclizine decreases levels of quetiapine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
meclizine decreases levels of quetiapine by pharmacodynamic antagonism. Use Caution/Monitor.
quetiapine increases effects of meclizine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. - rapacuronium
meclizine and rapacuronium both decrease cholinergic effects/transmission. Use Caution/Monitor.
- risperidone
meclizine decreases levels of risperidone by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
meclizine decreases levels of risperidone by pharmacodynamic antagonism. Use Caution/Monitor.
risperidone increases effects of meclizine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. - rocuronium
meclizine and rocuronium both decrease cholinergic effects/transmission. Use Caution/Monitor.
- scopolamine
meclizine and scopolamine both decrease cholinergic effects/transmission. Use Caution/Monitor.
- solifenacin
meclizine and solifenacin both decrease cholinergic effects/transmission. Use Caution/Monitor.
- stiripentol
stiripentol, meclizine. Either increases effects of the other by sedation. Use Caution/Monitor. Concomitant use stiripentol with other CNS depressants, including alcohol, may increase the risk of sedation and somnolence.
- succinylcholine
succinylcholine increases and meclizine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- thioridazine
meclizine decreases levels of thioridazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
meclizine decreases levels of thioridazine by pharmacodynamic antagonism. Use Caution/Monitor.
thioridazine increases effects of meclizine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. - thiothixene
meclizine decreases levels of thiothixene by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
meclizine decreases levels of thiothixene by pharmacodynamic antagonism. Use Caution/Monitor.
thiothixene increases effects of meclizine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. - tiotropium
meclizine and tiotropium both decrease cholinergic effects/transmission. Use Caution/Monitor.
- tolterodine
meclizine and tolterodine both decrease cholinergic effects/transmission. Use Caution/Monitor.
- trazodone
meclizine and trazodone both decrease cholinergic effects/transmission. Use Caution/Monitor.
- trifluoperazine
meclizine decreases levels of trifluoperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
meclizine decreases levels of trifluoperazine by pharmacodynamic antagonism. Use Caution/Monitor.
trifluoperazine increases effects of meclizine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. - trihexyphenidyl
meclizine and trihexyphenidyl both decrease cholinergic effects/transmission. Use Caution/Monitor. Potential for additive anticholinergic effects.
- trimipramine
meclizine and trimipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.
- trospium chloride
meclizine and trospium chloride both decrease cholinergic effects/transmission. Use Caution/Monitor.
- vecuronium
meclizine and vecuronium both decrease cholinergic effects/transmission. Use Caution/Monitor.
- ziprasidone
meclizine decreases levels of ziprasidone by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
meclizine decreases levels of ziprasidone by pharmacodynamic antagonism. Use Caution/Monitor.
ziprasidone increases effects of meclizine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. - zotepine
meclizine decreases levels of zotepine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
meclizine decreases levels of zotepine by pharmacodynamic antagonism. Use Caution/Monitor.
Minor (10)
- amikacin
meclizine, amikacin. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Ototoxicity of aminoglycoside may be masked.
- digoxin
meclizine increases levels of digoxin by unspecified interaction mechanism. Minor/Significance Unknown.
- dimenhydrinate
dimenhydrinate increases toxicity of meclizine by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.
- donepezil
donepezil decreases effects of meclizine by pharmacodynamic antagonism. Minor/Significance Unknown.
- galantamine
galantamine decreases effects of meclizine by pharmacodynamic antagonism. Minor/Significance Unknown.
- gentamicin
meclizine, gentamicin. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Ototoxicity of aminoglycoside may be masked.
- neomycin PO
meclizine, neomycin PO. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Ototoxicity of aminoglycoside may be masked.
- paromomycin
meclizine, paromomycin. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Ototoxicity of aminoglycoside may be masked.
- streptomycin
meclizine, streptomycin. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Ototoxicity of aminoglycoside may be masked.
- tobramycin
meclizine, tobramycin. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Ototoxicity of aminoglycoside may be masked.
Adverse Effects
Frequency Not Defined
Drowsiness
Thickening of bronchial secretions
Acute glaucoma attack
Blurred vision (rare)
Constipation
Fatigue
Vomiting
Xerostomia
Headache
Dry mouth
Urinary retention
Warnings
Contraindications
Hypersensitivity
Cautions
Use cautioin in obstructive genitourinary tract disease, asthma, pyloric or duodenal obstruction, prostatic hyperplasia, narrow angle glaucoma
Hepatic impairment may increase meclizine systemic exposure
Renal impairment may increase meclizine or metabolite accumulation
May impair physical or mental abilities; use caution when operating heavy machinery or performing tasks which require mental alertness
Pregnancy & Lactation
Pregnancy category: B
Lactation: Not known if excreted in milk; use caution
Pregnancy Categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk. C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done. D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk. X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist. NA: Information not available.Pharmacology
Mechanism of Action
Antihistamine with activity against nebulized histamine; blocks vasodepressor response to histamine, with slight blocking action against acetylcholine
Absorption
Onset: 30-60 min
Duration: 12-24 hr
Peak plasma time: 3 hr
Distribution
Vd: 7 L/kg
Metabolism
In vitro study found CYP2D6 the dominant metabolic enzyme
Elimination
Half-life: 5 hr
Excretion: Urine, feces
Pharmacogenomics
Genetic polymorphism of CYP2D6 that results in extensive-, poor-, intermediate- and ultrarapid metabolizer phenotypes could contribute to large interindividual variability in meclizine exposure
Images
BRAND | FORM. | UNIT PRICE | PILL IMAGE |
---|---|---|---|
Travel-Ease (meclizine) oral - | 25 mg tablet | ![]() | |
Motion Sickness Relief (meclizine) oral - | 25 mg chewable tablet | ![]() | |
meclizine oral - | 25 mg tablet | ![]() | |
meclizine oral - | 25 mg chewable tablet | ![]() | |
meclizine oral - | 25 mg tablet | ![]() | |
meclizine oral - | 12.5 mg tablet | ![]() | |
meclizine oral - | 25 mg chewable tablet | ![]() | |
meclizine oral - | 25 mg tablet | ![]() | |
meclizine oral - | 25 mg tablet | ![]() | |
meclizine oral - | 12.5 mg tablet | ![]() | |
meclizine oral - | 25 mg tablet | ![]() | |
meclizine oral - | 12.5 mg tablet | ![]() | |
meclizine oral - | 25 mg chewable tablet | ![]() | |
meclizine oral - | 12.5 mg tablet | ![]() | |
meclizine oral - | 25 mg chewable tablet | ![]() | |
meclizine oral - | 25 mg tablet | ![]() | |
meclizine oral - | 12.5 mg tablet | ![]() | |
meclizine oral - | 25 mg tablet | ![]() | |
meclizine oral - | 25 mg tablet | ![]() | |
meclizine oral - | 25 mg tablet | ![]() | |
meclizine oral - | 12.5 mg tablet | ![]() | |
meclizine oral - | 12.5 mg tablet | ![]() | |
meclizine oral - | 12.5 mg tablet | ![]() | |
meclizine oral - | 25 mg tablet | ![]() | |
meclizine oral - | 12.5 mg tablet | ![]() | |
meclizine oral - | 25 mg tablet | ![]() | |
meclizine oral - | 12.5 mg tablet | ![]() | |
meclizine oral - | 12.5 mg tablet | ![]() |
Copyright © 2010 First DataBank, Inc.
Patient Handout
meclizine oral
MECLIZINE - ORAL
(MEK-li-zeen)
COMMON BRAND NAME(S): Antivert, Vertin
USES: Meclizine is an antihistamine that is used to prevent and treat nausea, vomiting, and dizziness caused by motion sickness. It may also be used to reduce dizziness and loss of balance (vertigo) caused by inner ear problems.
HOW TO USE: Follow all directions on the product package. If your doctor has prescribed this medication, take it as directed. If you have any questions, ask your doctor or pharmacist.Take this medication by mouth with or without food. If you are taking the chewable tablets, chew the tablet thoroughly before swallowing.The dosage is based on your medical condition and response to treatment. Do not increase your dose or take this medication more often than directed.To prevent motion sickness, take the first dose one hour before starting activity such as travel.Tell your doctor if your condition does not improve or if it worsens.
SIDE EFFECTS: Drowsiness, dry mouth, and tiredness may occur. If any of these effects last or get worse, tell your doctor or pharmacist promptly.To relieve dry mouth, suck (sugarless) hard candy or ice chips, chew (sugarless) gum, drink water, or use a saliva substitute.If your doctor has directed you to use this medication, remember that your doctor has judged that the benefit to you is greater than the risk of side effects. Many people using this medication do not have serious side effects.Tell your doctor right away if you have any serious side effects, including: mental/mood changes (such as restlessness, confusion), fast/irregular heartbeat, shaking (tremor), difficulty urinating.Get medical help right away if you have any very serious side effects, including: seizures.A very serious allergic reaction to this drug is rare. However, get medical help right away if you notice any symptoms of a serious allergic reaction, including: rash, itching/swelling (especially of the face/tongue/throat), severe dizziness, trouble breathing.This is not a complete list of possible side effects. If you notice other effects not listed above, contact your doctor or pharmacist.In the US -Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 or at www.fda.gov/medwatch.In Canada - Call your doctor for medical advice about side effects. You may report side effects to Health Canada at 1-866-234-2345.
PRECAUTIONS: Before taking meclizine, tell your doctor or pharmacist if you are allergic to it; or if you have any other allergies. This product may contain inactive ingredients, which can cause allergic reactions or other problems. Talk to your pharmacist for more details.Before using this medication, tell your doctor or pharmacist your medical history, especially of: breathing problems (such as asthma, emphysema), high pressure in the eye (glaucoma), heart problems, high blood pressure, seizures, stomach/intestine problems (such as ulcers, blockage), overactive thyroid (hyperthyroidism), difficulty urinating (for example, due to enlarged prostate), liver problems, kidney problems.This drug may make you drowsy. Alcohol or marijuana (cannabis) can make you more drowsy. Do not drive, use machinery, or do anything that needs alertness until you can do it safely. Avoid alcoholic beverages. Talk to your doctor if you are using marijuana (cannabis).Before having surgery, tell your doctor or dentist about all the products you use (including prescription drugs, nonprescription drugs, and herbal products).Children may be more sensitive to the side effects of this drug. This drug can often cause excitement in young children instead of drowsiness.Older adults may be more sensitive to the side effects of this drug, especially drowsiness, confusion, or trouble urinating. Drowsiness and confusion can increase the risk of falling.During pregnancy, this medication should be used only when clearly needed. Discuss the risks and benefits with your doctor.It is unknown if this drug passes into breast milk. Consult your doctor before breastfeeding.
DRUG INTERACTIONS: Drug interactions may change how your medications work or increase your risk for serious side effects. This document does not contain all possible drug interactions. Keep a list of all the products you use (including prescription/nonprescription drugs and herbal products) and share it with your doctor and pharmacist. Do not start, stop, or change the dosage of any medicines without your doctor's approval.Some products that may interact with this drug include: antihistamines applied to the skin (such as diphenhydramine cream, ointment, spray).Tell your doctor or pharmacist if you are taking other products that cause drowsiness such as opioid pain or cough relievers (such as codeine, hydrocodone), alcohol, marijuana (cannabis), drugs for sleep or anxiety (such as alprazolam, lorazepam, zolpidem), muscle relaxants (such as carisoprodol, cyclobenzaprine), or other antihistamines (such as cetirizine, diphenhydramine).Check the labels on all your medicines (such as allergy or cough-and-cold products) because they may contain ingredients that cause drowsiness. Ask your pharmacist about using those products safely.This medication may interfere with certain laboratory tests (including allergy skin test), possibly causing false test results. Make sure laboratory personnel and all your doctors know you use this drug.
OVERDOSE: If someone has overdosed and has serious symptoms such as passing out or trouble breathing, call 911. Otherwise, call a poison control center right away. US residents can call their local poison control center at 1-800-222-1222. Canada residents can call a provincial poison control center. Symptoms of overdose may include: severe drowsiness, seizures, widened pupils. In children, mental/mood changes (such as restlessness, irritability, hallucinations) may occur before drowsiness.
NOTES: Keep all medical and lab appointments.
MISSED DOSE: If you miss a dose, take it as soon as you remember. If it is near the time of the next dose, skip the missed dose. Take your next dose at the regular time. Do not double the dose to catch up.
STORAGE: Store at room temperature away from light and moisture. Do not store in the bathroom. Keep all medications away from children and pets.Do not flush medications down the toilet or pour them into a drain unless instructed to do so. Properly discard this product when it is expired or no longer needed. Consult your pharmacist or local waste disposal company.
Information last revised January 2023. Copyright(c) 2023 First Databank, Inc.
IMPORTANT: HOW TO USE THIS INFORMATION: This is a summary and does NOT have all possible information about this product. This information does not assure that this product is safe, effective, or appropriate for you. This information is not individual medical advice and does not substitute for the advice of your health care professional. Always ask your health care professional for complete information about this product and your specific health needs.
Formulary
Adding plans allows you to compare formulary status to other drugs in the same class.
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.